LKB1‐SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition

Abstract Metastatic uveal melanomas are highly resistant to all existing treatments. To address this critical issue, we performed a kinome‐wide CRISPR‐Cas9 knockout screen, which revealed the LKB1‐SIK2 module in restraining uveal melanoma tumorigenesis. Functionally, LKB1 loss enhances proliferation...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sarah Proteau, Imène Krossa, Chrystel Husser, Maxime Guéguinou, Federica Sella, Karine Bille, Marie Irondelle, Mélanie Dalmasso, Thibault Barouillet, Yann Cheli, Céline Pisibon, Nicole Arrighi, Sacha Nahon‐Estève, Arnaud Martel, Lauris Gastaud, Sandra Lassalle, Olivier Mignen, Patrick Brest, Nathalie M Mazure, Frédéric Bost, Stéphanie Baillif, Solange Landreville, Simon Turcotte, Dan Hasson, Saul Carcamo, Christophe Vandier, Emily Bernstein, Laurent Yvan‐Charvet, Mitchell P Levesque, Robert Ballotti, Corine Bertolotto, Thomas Strub
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Springer Nature 2023-11-01
Sarja:	EMBO Molecular Medicine
Aiheet:	calcium LKB1 SIK2 SLC8A1 uveal melanoma
Linkit:	https://doi.org/10.15252/emmm.202317719
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!